Rg3 treatment of hypoxic NSCLC cells decreased the expression of p-p65 and p65 in a concentration- and time-dependent manner, and NF-κB DNA binding in the Rg3 + cisplatin group was less than that of the two drugs used individually in hypoxic cells. This evidence concerns the gene NFKB1 and non-small cell lung carcinoma.